The global fight against HIV has reached a milestone that once appeared almost impossible. New HIV infections and AIDS-related deaths are now at their lowest levels in more than 30 years, while access to lifesaving treatment has expanded from fewer than eight million people in 2010 to more than 32 million.
Those achievements were highlighted at the 2026 United Nations High-Level Meeting on HIV/AIDS, where governments reviewed decades of scientific, political and community-led progress. The gathering produced a new international declaration intended to guide the world toward ending AIDS as a public health threat by 2030.
Yet the summit’s message was not simply celebratory. Funding reductions, unequal treatment access, restrictive laws and weakening community services could reverse years of progress. The latest figures show that the tools needed to control HIV already exist, but their success depends on whether countries continue financing and delivering them.
New HIV Infections Have Fallen Dramatically
Approximately 1.2 million people acquired HIV in 2025. That remains a serious global health burden, but it represents a 65 percent decline from the epidemic’s 1994 peak, when an estimated 3.5 million people acquired the virus in a single year.
Since 2010 alone, annual new infections have fallen by 42 percent, according to the latest UNAIDS global HIV statistics. Progress among children has been even greater, with new infections declining by 69 percent since 2010.
The reduction reflects several developments working together. Wider access to HIV testing allows infections to be identified earlier. Antiretroviral treatment suppresses the virus in people living with HIV, protecting their health while preventing sexual transmission when viral suppression is maintained. Condoms, pre-exposure prophylaxis, harm-reduction programmes and medicines that prevent transmission during pregnancy have also contributed.
The figures demonstrate that HIV prevention is not dependent on one single intervention. The strongest national responses combine medical treatment with testing, education, community outreach and legal environments in which people can seek care without fear of discrimination.
AIDS-Related Deaths Are at Their Lowest Level in Decades
Around 570,000 people died from AIDS-related illnesses in 2025. That figure represents a 73 percent reduction from the 2004 peak of approximately 2.1 million deaths and a 57 percent decline since 2010.
This progress is closely connected to the expansion of antiretroviral therapy. HIV treatment prevents the virus from damaging the immune system and allows many people with HIV to live long, healthy lives. At the end of 2025, approximately 32.1 million people were receiving treatment, compared with 7.6 million in 2010.
Treatment has transformed HIV from an infection that frequently progressed to AIDS and early death into a manageable chronic condition for people who are diagnosed and consistently receive effective medicine.
The achievement should not obscure the remaining loss of life. The latest figures still mean that someone died from an HIV-related cause approximately every minute during 2025. Many of these deaths were preventable because effective treatment already exists.
Treatment Access Has Expanded on an Extraordinary Scale
The global treatment cascade provides one of the clearest measures of progress. In 2025, 88 percent of people living with HIV knew their status. Among those who had been diagnosed, 89 percent were receiving treatment, and 95 percent of treated individuals had achieved viral suppression.
Across the entire population living with HIV, approximately 78 percent were on treatment and 74 percent were virally suppressed. These results move the world closer to the 95-95-95 targets, under which 95 percent of people with HIV know their status, 95 percent of diagnosed people receive treatment and 95 percent of treated people achieve viral suppression.
Viral suppression is especially important because it protects the individual’s immune system and prevents sexual transmission. This principle is widely communicated as “undetectable equals untransmittable,” or U=U.
The progress also means that more people are living with HIV than in earlier decades. UNAIDS estimated that 41 million people were living with the virus in 2025. That number reflects both continuing infections and the success of treatment in helping people live longer.
The UN Adopted New Targets for 2030
The June 2026 meeting brought together governments, scientists, community representatives, civil-society organisations and people living with HIV. Its central outcome was a new Political Declaration on HIV/AIDS, adopted by 149 countries, with eight voting against and 14 abstaining.
The declaration commits the international community to expanding treatment to 40 million people by 2030, including 38 million with suppressed viral loads. It also aims to provide antiretroviral-based prevention to 20 million people and reach 90 percent of those in need with effective prevention options.
The complete targets are outlined in UNAIDS’ summary of the 2026 Political Declaration. The agreement also renews the goal of reducing new infections and AIDS-related deaths by 90 percent from 2010 levels.
UNAIDS estimates that fully implementing the declaration could prevent an additional 3.2 million new HIV infections and 1.3 million AIDS-related deaths by 2030. Those projections show that political commitments made at the summit could produce measurable health outcomes rather than remaining symbolic statements.
Progress Is Still Deeply Unequal
Global averages can hide major differences between countries and populations. Seven countries have reduced new infections by almost 80 percent since 2010, and 11 have reached the 95-95-95 treatment targets. At the same time, new infections increased in three regions and 21 countries during 2025.
Approximately nine million people living with HIV were not receiving treatment. Children faced one of the largest gaps: only 55 percent of children aged 14 or younger had treatment access, compared with 79 percent of adults. Almost half of children living with HIV were consequently missing medicines that could protect their health.
Treatment coverage also differed by sex. Approximately 84 percent of adult women living with HIV received treatment, compared with 74 percent of adult men. Differences in testing behaviour, access to healthcare and social conditions can all influence these outcomes.
People facing criminalisation and discrimination remain disproportionately affected. UNAIDS estimates that the risk of acquiring HIV is 34 times higher among people who inject drugs, 18 times higher among gay men and other men who have sex with men, and 17 times higher among sex workers and transgender women than among the general adult population.
Funding Cuts Threaten to Reverse the Gains
The largest immediate threat may be financial. Approximately $17.6 billion was available for HIV programmes in low- and middle-income countries at the end of 2025, around 20 percent below the $21.9 billion UNAIDS says will be required annually by 2030.
International HIV financing declined from $8.8 billion in 2024 to $7.3 billion in 2025, its lowest level in almost two decades. Global development assistance also fell by 23 percent during the year.
The effects are already appearing in prevention services. Funding for condoms has reportedly fallen by more than 90 percent in some countries. A study covering 47 countries found major reductions in community-led services, including an 85 percent decline in services for gay men and other men who have sex with men and an 82 percent decline in services for sex workers.
These organisations often reach people who avoid conventional health facilities because of stigma, criminalisation or previous discrimination. Closing them can reduce testing and prevention access long before the consequences appear in official infection statistics.
New Prevention Technology Offers Another Opportunity
Scientific innovation gives the 2030 effort additional reasons for optimism. Long-acting prevention medicines could reduce dependence on daily pills and make HIV prevention easier to maintain.
Lenacapavir, a twice-yearly injectable medicine, has attracted particular attention after highly successful prevention trials. Public-health organisations are now examining how to make it available to millions of people who could benefit.
The technology will have limited global impact, however, unless pricing, manufacturing and distribution allow it to reach countries with the greatest need. The 2026 declaration therefore includes commitments to improve access to medicines, encourage technology transfer and strengthen local production.
The UN High-Level Meeting outcome emphasised equitable access to long-acting prevention and treatment rather than limiting new technology to wealthy markets.
Ending AIDS Is Possible, but Not Guaranteed
The latest data tell two stories simultaneously. The first is an extraordinary public-health success. New infections and AIDS-related deaths have fallen to levels not seen for more than three decades, while treatment now reaches tens of millions of people.
The second story is one of unfinished and increasingly fragile progress. More than one million people still acquire HIV annually, hundreds of thousands continue dying, and millions remain without treatment. Prevention programmes are losing funding precisely when new medical technologies could accelerate progress.
The UN summit showed that ending AIDS as a public health threat is no longer an unrealistic ambition. Some countries have already demonstrated how dramatic reductions can be achieved through sustained treatment, prevention, community leadership and political support.
The remaining challenge is protecting those systems long enough for every region and population to experience the same progress. The science has advanced. The targets have been agreed. Whether the world reaches them will now depend on financing, access and the willingness to ensure that those most affected are not left behind.
